Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.7143.

A number of research firms have commented on DAWN. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. Piper Sandler raised their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. TD Cowen initiated coverage on Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating and a $34.00 price objective for the company. Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th.

Insider Activity

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 4,062 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $36,192.42. Following the completion of the sale, the chief financial officer owned 294,715 shares of the company’s stock, valued at approximately $2,625,910.65. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Adam Dubow sold 4,319 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $38,482.29. Following the completion of the sale, the insider owned 62,626 shares in the company, valued at approximately $557,997.66. This trade represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 28,001 shares of company stock valued at $249,489. Insiders own 6.20% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

A number of large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its stake in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after buying an additional 1,029 shares during the period. Federated Hermes Inc. bought a new stake in shares of Day One Biopharmaceuticals in the third quarter worth about $39,000. Quarry LP bought a new stake in shares of Day One Biopharmaceuticals in the third quarter worth about $49,000. Ameritas Investment Partners Inc. raised its position in shares of Day One Biopharmaceuticals by 44.5% during the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after purchasing an additional 2,264 shares during the period. Finally, CWM LLC lifted its holdings in shares of Day One Biopharmaceuticals by 32.4% during the 4th quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after purchasing an additional 2,051 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Trading Up 0.7%

Shares of NASDAQ:DAWN opened at $12.03 on Tuesday. Day One Biopharmaceuticals has a 1-year low of $5.64 and a 1-year high of $13.53. The stock has a market capitalization of $1.24 billion, a P/E ratio of -7.91 and a beta of -1.27. The business has a 50-day moving average price of $9.42 and a two-hundred day moving average price of $8.03.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.09. The company had revenue of $39.80 million for the quarter, compared to analyst estimates of $38.20 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The company’s revenue for the quarter was down 57.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.38 EPS. As a group, equities analysts predict that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.